10:52:56 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-05-31 Kvartalsrapport 2024-Q1
2024-05-31 Årsstämma 2024
2024-03-29 Bokslutskommuniké 2023
2023-11-30 Kvartalsrapport 2023-Q3
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-31 Årsstämma 2023
2023-05-31 Kvartalsrapport 2023-Q1
2023-05-02 Ordinarie utdelning BIOSGN 0.00 SEK
2023-03-31 Bokslutskommuniké 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-06-30 Årsstämma 2022
2022-05-31 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning BIOSGN 0.00 SEK
2022-03-31 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Biosergen är verksamt inom bioteknik. Bolaget är specialiserat inom forskning och utveckling av diverse läkemedel. Produktportföljen inkluderar exempelvis bolagets produkt BSG005, ett svampdödande läkemedel i klinisk fas. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs i Norge. Biosergen grundades år 2004 och har sitt huvudkontor i Solna.
2023-08-28 15:25:00

Stockholm, Sweden - August 28, 2023 - Biosergen AB ("Biosergen" or the "Company") today announces the outcome of the exercise of warrants series TO2, which were issued in connection with the Company's rights issue of units on Nasdaq First North Growth Market in October 2022. In total, 8,258,203 warrants series TO2, corresponding to approximately 96.1 percent of the total number of outstanding warrants series TO2, were exercised for subscription of 8,258,203 shares at an exercise price of SEK 0.66 per share. Biosergen will thereby receive approximately SEK 5.5 million before issuing costs.

The exercise period for exercise of the warrants series TO2 took place during the period from and including August 14, 2023, up to and including August 25, 2023. The exercise price per share was set to SEK 0.66 and each warrant series TO2 entitled to subscription of one (1) new share in the Company.

In total, 8,258,203 warrants series TO2 were exercised for subscription of the same number of shares, meaning that approximately 96.1 percent of all outstanding warrants series TO2 were exercised for subscription of shares. Through the warrant exercise, Biosergen receives approximately SEK 5.5 million before issuing costs.

Exercised warrants have been replaced with interim shares (IA), pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted to shares within approximately three (3) weeks.

Number of shares, share capital and dilution
Through the exercise of the warrants series TO2, the number of shares in Biosergen increases by 8,258,203 shares, from 42,427,660 shares to a total of 50,685,863 shares. The share capital increases by SEK 206,455.075, from SEK 1,060,691.500 to SEK 1,267,146.575.

For existing shareholders who did not exercise any warrants series TO2, the dilution amounts to approximately 16.3 percent calculated on the number of shares and votes in the Company before the warrant exercise.

Advisors
Mangold Fondkommission AB is the financial advisor and Setterwalls Advokatbyrå AB is the legal advisor to Biosergen in connection with the exercise of warrants series TO2.